1.New Therapeutic Strategies against Helicobacter pylori.
Bong Ku KANG ; Sung Min PARK ; Byung Wook KIM
The Korean Journal of Gastroenterology 2014;63(3):146-150
The standard therapy for Helicobacter pylori infection in Korea is a triple-drug regimen consisting of a proton pump inhibitor with two antibiotics such as clarithromycin, amoxicillin, and metronidazole. However, as the eradication rate of this regimen has declined over the past decade, this prompted the formulation of new therapeutic regimens. New therapeutic strategies against H. pylori infection that had been tried all over the world include sequential therapy, concomitant therapy, and tailored therapy This article will review the basic concepts and the results of previous clinical trials on the aforementioned new therapeutic regiments.
Amoxicillin/pharmacology/therapeutic use
;
Anti-Bacterial Agents/pharmacology/*therapeutic use
;
Clarithromycin/pharmacology/therapeutic use
;
Disease Eradication/trends
;
Drug Therapy, Combination
;
Helicobacter Infections/*drug therapy
;
*Helicobacter pylori/drug effects
;
Humans
;
Nitroimidazoles/pharmacology/therapeutic use
;
Proton Pump Inhibitors/pharmacology/therapeutic use
2.Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Baojun SUO ; Xueli TIAN ; Hua ZHANG ; Haoping LU ; Cailing LI ; Yuxin ZHANG ; Xinlu REN ; Xingyu YAO ; Liya ZHOU ; Zhiqiang SONG
Chinese Medical Journal 2023;136(8):933-940
BACKGROUND:
Given the general unavailability, common adverse effects, and complicated administration of tetracycline, the clinical application of classic bismuth quadruple therapy (BQT) is greatly limited. Whether minocycline can replace tetracycline for Helicobacter pylori ( H . pylori ) eradication is unknown. We aimed to compare the eradication rate, safety, and compliance between minocycline- and tetracycline-containing BQT as first-line regimens.
METHODS:
This randomized controlled trial was conducted on 434 naïve patients with H . pylori infection. The participants were randomly assigned to 14-day minocycline-containing BQT group (bismuth potassium citrate 110 mg q.i.d., esomeprazole 20 mg b.i.d., metronidazole 400 mg q.i.d., and minocycline 100 mg b.i.d.) and tetracycline-containing BQT group (bismuth potassium citrate/esomeprazole/metronidazole with doses same as above and tetracycline 500 mg q.i.d.). Safety and compliance were assessed within 3 days after eradication. Urea breath test was performed at 4-8 weeks after eradication to evaluate outcome. We used a noninferiority test to compare the eradication rates of the two groups. The intergroup differences were evaluated using Pearson chi-squared or Fisher's exact test for categorical variables and Student's t -test for continuous variables.
RESULTS:
As for the eradication rates of minocycline- and tetracycline-containing BQT, the results of both intention-to-treat (ITT) and per-protocol (PP) analyses showed that the difference rate of lower limit of 95% confidence interval (CI) was >-10.0% (ITT analysis: 181/217 [83.4%] vs . 180/217 [82.9%], with a rate difference of 0.5% [-6.9% to 7.9%]; PP analysis: 177/193 [91.7%] vs . 176/191 [92.1%], with a rate difference of -0.4% [-5.6% to 6.4%]). Except for dizziness more common (35/215 [16.3%] vs . 13/214 [6.1%], P = 0.001) in minocycline-containing therapy groups, the incidences of adverse events (75/215 [34.9%] vs . 88/214 [41.1%]) and compliance (195/215 [90.7%] vs . 192/214 [89.7%]) were similar between the two groups.
CONCLUSION:
The eradication efficacy of minocycline-containing BQT was noninferior to tetracycline-containing BQT as first-line regimen for H . pylori eradication with similar safety and compliance.
TRIAL REGISTRATION
ClinicalTrials.gov, ChiCTR 1900023646.
Humans
;
Bismuth/therapeutic use*
;
Metronidazole/therapeutic use*
;
Esomeprazole/pharmacology*
;
Minocycline/pharmacology*
;
Helicobacter pylori
;
Potassium Citrate/therapeutic use*
;
Anti-Bacterial Agents
;
Tetracycline/adverse effects*
;
Helicobacter Infections/drug therapy*
;
Drug Therapy, Combination
;
Amoxicillin
3.Dual therapy for Helicobacter pylori infection.
Miao DUAN ; Jing LIU ; Xiuli ZUO
Chinese Medical Journal 2023;136(1):13-23
Bismuth-containing quadruple therapy (BQT) has long been recommended for Helicobacter pylori ( H. pylori ) eradication in China. Meanwhile, in the latest national consensus in China, dual therapy (DT) comprising an acid suppressor and amoxicillin has also been recommended. In recent years, the eradication rate of H. pylori has reached >90% using DT, which has been used not only as a first-line treatment but also as a rescue treatment. Compared with BQT, DT has great potential for H. pylori eradication; however, it has some limitations. This review summarizes the development of DT and its application in H. pylori eradication. The H. pylori eradication rates of DT were comparable to or even higher than those of BQT or standard triple therapy, especially in the first-line treatment. The incidence of adverse events associated with DT was lower than that with other therapies. Furthermore, there were no significant differences in the effects of dual and quadruple therapies on gastrointestinal microecology. In the short term, H. pylori eradication causes certain fluctuations in the gastrointestinal microbiota; however, in the long term, the gastrointestinal microbiota eventually returns to its normal state. In the penicillin-naïve population, patients receiving DT have a high eradiation rate, better compliance, lower incidence of adverse reactions, and lower primary and secondary resistance to amoxicillin. These findings suggest the safety, efficacy, and potential of DT for H. pylori eradication.
Humans
;
Helicobacter Infections/drug therapy*
;
Anti-Bacterial Agents/pharmacology*
;
Helicobacter pylori
;
Proton Pump Inhibitors
;
Drug Therapy, Combination
;
Amoxicillin/therapeutic use*
;
Treatment Outcome
4.Changes in the Eradication Rate of Conventional Triple Therapy for Helicobacter pylori Infection in Korea.
The Korean Journal of Gastroenterology 2014;63(3):141-145
Although, the prevalence of Helicobacter pylori infection in Korea has declined owing to the eradication therapy, recent seroprevalence of H. pylori infection is still reported to be as high as 54.4%. Until now, "standard regimen" for eradication of H. pylori has been conventional triple therapy consisting of proton pump inhibitor, amoxicillin, and clarithromycin. However, with the increase in antibiotic resistance, especially against clarithromycin, the eradication rate of conventional triple therapy has steadily declined during the past 13 years in Korea. Present eradication rate of standard triple therapy is reported to be less than 80%, which is the Maginot line of efficacy for the currently available regimen. Therefore, new first line eradication regimen is needed to enhance the eradication rate of H. pylori infection.
Amoxicillin/pharmacology/therapeutic use
;
Anti-Bacterial Agents/pharmacology/*therapeutic use
;
Asian Continental Ancestry Group
;
Clarithromycin/pharmacology/therapeutic use
;
Disease Eradication/trends
;
Drug Administration Schedule
;
Drug Therapy, Combination
;
Helicobacter Infections/*drug therapy
;
*Helicobacter pylori/drug effects
;
Humans
;
Proton Pump Inhibitors/therapeutic use
;
Republic of Korea
5.Evaluation of antibacterial activity of amoxycillin sodium and clavulanate potassium and the pharmacoeconomics in the therapy of acute respiratory infection.
Feng XU ; Ping ZHAO ; Yan-hong LUO ; Feng-wu KUANG ; Lan LIU ; Chang-lin LIU
Chinese Journal of Pediatrics 2003;41(5):352-356
OBJECTIVETo explore the antibacterial activity of amoxycillin sodium and clavulanate potassium (trade name: Anqi) in vitro and the pharmacoeconomics in the therapy of acute respiratory infection.
METHODSMinimal inhibition concentration (MIC), minimal bactericidal concentration (MBC) and bactericidal curve of amoxycillin sodium and clavulanate potassium against common pathogens were determined and compared with some other same kind of antibiotics without beta-Lactamase inhibitor. Eighty cases diagnosed as respiratory infection were randomly divided into 4 groups: group 1 was treated with i.v. Anqi; group 2 was treated with i.v. Anqi and oral consecutive strategy; group 3 was treated with iv ampicillin and sulbactam; group 4 was treated with i.v. cefuroxime. The clinical therapeutic effects were observed and cost-effectiveness analyzed.
RESULTSIn terms of MIC, MBC and bactericidal curve of 135 bacterial strains, Anqi was superior to the other same-kind antibiotics without beta-lactamase inhibitor, this effect was especially obvious on Klebsiella pneumoniae and Escherichia coli which can produce extended spectrum beta-lactamases (ESBLs). The cost-effectiveness of the consecutive therapy group was the best.
CONCLUSIONAnqi has a wide antimicrobial spectrum and strong effect on the bacteria producing ESBLs, the consecutive therapy strategy should be clinically recommended.
Amoxicillin ; pharmacology ; therapeutic use ; Anti-Bacterial Agents ; pharmacology ; therapeutic use ; Bacteria ; drug effects ; Child ; Child, Preschool ; Clavulanic Acid ; pharmacology ; therapeutic use ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; therapeutic use ; Female ; Humans ; Infant ; Male ; Microbial Sensitivity Tests ; Respirovirus Infections ; drug therapy ; economics ; Treatment Outcome
6.Preliminary study on in-vitro induction of antibiotic resistance in Helicobacter pylori strains isolated from children.
Wei-hui YAN ; Jie CHEN ; Hua-jian HU ; Jin-dan YU ; Xiao-lei HUANG ; Zhong-yue LI
Chinese Journal of Pediatrics 2007;45(9):708-711
OBJECTIVEMany clinical studies indicated that Helicobacter pylori (Hp) strains rarely acquired resistance to amoxicillin but easily to clarithromycin and metronidazole. However, it was unclear whether the antibiotic resistance of Hp strains was induced or passively selected during long-term or frequent treatment with metronidazole, clarithromycin and amoxicillin. To compare the propensity of acquired resistance to antibiotics, Hp strains were exposed to amoxicillin, clarithromycin and metronidazole in vitro in this study.
METHODSAll Hp strains were clinical isolates, derived from biopsy specimens of patients taken during endoscopy in the Affiliated Children's Hospital, Zhejiang University School of Medicine from December 2004 to July 2005. To seek susceptible strains, the minimum inhibitory concentrations (MICs) of the three antibiotics were determined by using Epsilometer test (E-test) method. In vitro induction was carried out on serially doubling concentrations of antibiotics incorporated into agar. Isolates were also transferred at least three times on antimicrobial agent-free medium, followed by a redetermination of the final MICs to assess the stability of the selected resistance.
RESULTS7 strains were exposed to antibiotics in vitro. After 6 - 17 passages on antibiotic plates, 7 and 3 strains respectively acquired resistance to metronidazole and clarithromycin, while none of the strains were resistant to amoxicillin. The inductive folds were different among three groups: 8 - 128 folds in metronidazole group; 1 - 256 folds in clarithromycin group; 2 - 16 folds in amoxicillin group. After three transfers on antimicrobial agent-free medium, the MICs decreased significantly in amoxicillin group (P < 0.05) but had no change in metronidazole group and clarithromycin group (P > 0.05).
CONCLUSIONSThe metronidazole resistance in Hp was easily selected. Strains resistant to clarithromycin could be selected, but the amoxicillin resistance could not be selected after in vitro induction for Hp isolated from children. The correlation between in vitro and in vivo outcomes suggests that acquired resistance was the main cause for the resistance in Hp strains. The laboratory results of in vitro antibiotic induction could help predict the actual rate of resistance and select appropriate antibiotics for treatment.
Amoxicillin ; pharmacology ; Anti-Bacterial Agents ; pharmacology ; therapeutic use ; Anti-Infective Agents ; pharmacology ; therapeutic use ; Biopsy ; Child ; Clarithromycin ; pharmacology ; Drug Resistance, Microbial ; drug effects ; Drug Resistance, Multiple, Bacterial ; drug effects ; Helicobacter Infections ; drug therapy ; microbiology ; Helicobacter pylori ; drug effects ; isolation & purification ; Humans ; Metronidazole ; pharmacology ; Microbial Sensitivity Tests ; methods ; Tetracycline ; pharmacology
7.Regional Difference of Antibiotic Resistance of Helicobacter pylori Strains in Korea.
Jae Yeon KIM ; Nayoung KIM ; Sung Jung KIM ; Gwang Ho BAIK ; Gwang Ha KIM ; Jung Mogg KIM ; Ryoung Hee NAM ; Hong Bin KIM ; Dong Ho LEE ; Hyun Chae JUNG ; In Sung SONG
The Korean Journal of Gastroenterology 2011;57(4):221-229
BACKGROUND/AIMS: This study was performed to compare the prevalence rates of primary antibiotic resistance in Helicobacter pylori (H. pylori) isolates among different regions of Korea. METHODS: H. pylori were isolated from gastric mucosal biopsy specimens of 99 Koreans who lived in Gyeonggi (n=40), Kangwon province (n=40) and Busan (n=19) from April to August in 2008. All the patients had no history of H. pylori eradication therapy. The susceptibilities of the H. pylori isolates to amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin, and moxifloxacin were tested according to the agar dilution method. RESULTS: There was a difference in resistance to clarithromycin in three institutes located among Gyeonggi (32.5%), Kangwon province (12.5%) and Busan (42.1%) by One way ANOVA test (p=0.027) and nonparametric Kruskal Wallis test (p=0.027). However, by post-hoc analysis, there was no statistically significant difference among three regions. Similarly, the other 7 antibiotics (amoxicillin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin) did not show any significant difference. CONCLUSIONS: There was no significant regional difference of the primary antibiotic resistance of H. pylori. However, the included patient number might not be enough for this conclusion demanding further evaluations.
Amoxicillin/pharmacology
;
Anti-Bacterial Agents/pharmacology/therapeutic use
;
Aza Compounds/pharmacology
;
Azithromycin/pharmacology
;
Ciprofloxacin/pharmacology
;
Clarithromycin/pharmacology
;
*Drug Resistance, Bacterial
;
Female
;
Helicobacter Infections/*epidemiology/microbiology
;
Helicobacter pylori/*drug effects/isolation & purification
;
Humans
;
Male
;
Metronidazole/pharmacology
;
Microbial Sensitivity Tests
;
Middle Aged
;
Ofloxacin/pharmacology
;
Quinolines/pharmacology
;
Republic of Korea/epidemiology
;
Tetracycline/pharmacology
8.Regional Difference of Antibiotic Resistance of Helicobacter pylori Strains in Korea.
Jae Yeon KIM ; Nayoung KIM ; Sung Jung KIM ; Gwang Ho BAIK ; Gwang Ha KIM ; Jung Mogg KIM ; Ryoung Hee NAM ; Hong Bin KIM ; Dong Ho LEE ; Hyun Chae JUNG ; In Sung SONG
The Korean Journal of Gastroenterology 2011;57(4):221-229
BACKGROUND/AIMS: This study was performed to compare the prevalence rates of primary antibiotic resistance in Helicobacter pylori (H. pylori) isolates among different regions of Korea. METHODS: H. pylori were isolated from gastric mucosal biopsy specimens of 99 Koreans who lived in Gyeonggi (n=40), Kangwon province (n=40) and Busan (n=19) from April to August in 2008. All the patients had no history of H. pylori eradication therapy. The susceptibilities of the H. pylori isolates to amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin, and moxifloxacin were tested according to the agar dilution method. RESULTS: There was a difference in resistance to clarithromycin in three institutes located among Gyeonggi (32.5%), Kangwon province (12.5%) and Busan (42.1%) by One way ANOVA test (p=0.027) and nonparametric Kruskal Wallis test (p=0.027). However, by post-hoc analysis, there was no statistically significant difference among three regions. Similarly, the other 7 antibiotics (amoxicillin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin) did not show any significant difference. CONCLUSIONS: There was no significant regional difference of the primary antibiotic resistance of H. pylori. However, the included patient number might not be enough for this conclusion demanding further evaluations.
Amoxicillin/pharmacology
;
Anti-Bacterial Agents/pharmacology/therapeutic use
;
Aza Compounds/pharmacology
;
Azithromycin/pharmacology
;
Ciprofloxacin/pharmacology
;
Clarithromycin/pharmacology
;
*Drug Resistance, Bacterial
;
Female
;
Helicobacter Infections/*epidemiology/microbiology
;
Helicobacter pylori/*drug effects/isolation & purification
;
Humans
;
Male
;
Metronidazole/pharmacology
;
Microbial Sensitivity Tests
;
Middle Aged
;
Ofloxacin/pharmacology
;
Quinolines/pharmacology
;
Republic of Korea/epidemiology
;
Tetracycline/pharmacology